[{"orgOrder":0,"company":"Aleor Dermaceuticals","sponsor":"Alembic Pharmaceuticals Limited","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Mupirocin","moa":"Isoleucine-tRNA ligase","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Aleor Dermaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Aleor Dermaceuticals \/ Alembic Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Aleor Dermaceuticals \/ Alembic Pharma"}]

Find Clinical Drug Pipeline Developments & Deals for 14C-Labeled Mupirocin

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPHI Middle east
                          Not Confirmed
                          CPHI Middle east
                          Not Confirmed

                          Details : Mupirocin cream USP, 2% is indicated for the treatment of secondarily infected traumatic skin lesions due to susceptible strains of S. aureus and S. pyogenes.

                          Brand Name : Mupirocin

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          November 17, 2021

                          Lead Product(s) : Mupirocin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Alembic Pharmaceuticals Limited

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank